Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 1
2007 1
2010 1
2011 1
2019 1
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
Rare case of congenital generalized lipodystrophy type 1.
Shyam Sundar CM, Subrahmanyam KAV. Shyam Sundar CM, et al. Among authors: subrahmanyam kav. Indian J Med Res. 2020 Nov;152(Suppl 1):S181-S182. doi: 10.4103/ijmr.IJMR_2275_19. Indian J Med Res. 2020. PMID: 35345194 Free PMC article. No abstract available.
A rare case of 46XX ovotesticular disorder of sex development.
Reddy SSL, Subrahmanyam KAV. Reddy SSL, et al. Among authors: subrahmanyam kav. Indian J Med Res. 2020 Nov;152(Suppl 1):S109. doi: 10.4103/ijmr.IJMR_2178_19. Indian J Med Res. 2020. PMID: 35345152 Free PMC article. No abstract available.
Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
Ajmani AK, Agrawal A, Prasad BLN, Basu I, Shembalkar J, Manikanth N, Subrahmanyam KAV, Srinivasa M, Chawla M, Srivastava MK, Jebasingh F, Achappa B, Agrawal RP, Pulichikkat RK, Meena R, Bhatia S, Gupta SK, Dange A, Srivastava A, Trailokya A, Shahavi V, Shende S. Ajmani AK, et al. Among authors: subrahmanyam kav. Diabetes Res Clin Pract. 2019 Nov;157:107860. doi: 10.1016/j.diabres.2019.107860. Epub 2019 Sep 14. Diabetes Res Clin Pract. 2019. PMID: 31526825 Clinical Trial.